Actively Recruiting

Phase 3
Age: 19Years +
All Genders
NCT06291207

A Study to Evaluate the Efficacy and Safety of AD-224

Led by Addpharma Inc. · Updated on 2025-02-04

252

Participants Needed

1

Research Sites

63 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the efficacy and safety of AD-224

CONDITIONS

Official Title

A Study to Evaluate the Efficacy and Safety of AD-224

Who Can Participate

Age: 19Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent
  • Patients with Essential Hypertension
  • Other inclusions applied
Not Eligible

You will not qualify if you...

  • Patient with Secondary Hypertension
  • Other exclusions applied

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Seoul National University Bundang Hospital

Seongnam-si, South Korea

Actively Recruiting

Loading map...

Research Team

J

JeongEun Park

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Evaluate the Efficacy and Safety of AD-224 | DecenTrialz